Journal Basic Info
- Impact Factor: 0.285**
- H-Index: 6
- ISSN: 2638-4558
- DOI: 10.25107/2638-4558
Major Scope
- Orthopedics & Rheumatology
- Anesthesiology and Pain Medicine
- Nutrition and Dietetics
- Nursing
- Leukemia
- Physiotherapy
- Sexual Health
- Epidemiology
Abstract
Citation: Clin Case Rep Int. 2020;4(1):1147.DOI: 10.25107/2638-4558.1147
A Patient with BRAFV600E - Mutant Lung Adenocarcinoma Responding to Dabrafenib and Trametinib
Chloé Denis and Frédérique Bustin
Department of Oncology, University of Liège Hospital, Belgium Department of Pneumology, CHR de la Citadelle, Belgium
*Correspondance to: Chloé Denis
PDF Full Text Case Report | Open Access
Abstract:
BRAF is a gene that encodes a protein belonging to the RAF family of protein kinases. This protein transduces signals via the mitogen-activated protein kinase pathway to the nucleus of receptive cells. We report another case of BRAFV600E-mutant lung adenocarcinoma responding to dabrafenib and trametinib treatment.
Keywords:
Cite the Article:
Denis C, Bustin F. A Patient with BRAFV600E - Mutant Lung Adenocarcinoma Responding to Dabrafenib and Trametinib. Clin Case Rep Int. 2020; 4: 1147.
